In the U.S., having sickle cell disease (SCD) continues to place a heavy clinical burden on patients, who often require multiple medications, frequent blood transfusions, and the use of opioids to control pain. Most individuals with SCD report high barriers to healthcare, with poor access to treatments and little…
News
Newborns with sickle cell trait (SCT), meaning they carry a mutation in one copy of the HBB gene but do not have sickle cell disease (SCD), show abnormalities in certain biological markers that can be detected within the first week after birth, a new study reports. Differences were found in markers…
A blood test measuring levels of the protein cystatin C may provide a more reliable way to monitor for kidney problems in children and young adults with sickle cell disease (SCD), a small study suggests. Data showed that commonly used formulas based on creatinine-to-protein ratio, a well-established kidney…
Children with sickle cell disease (SCD) are about seven times more likely to have asthma than their unaffected siblings, with odds increasing with age, according to a study in the U.S. These findings highlight the importance of more frequent screening to protect the lungs and prevent asthma-related complications in…
A high dose of pociredir, Fulcrum Therapeutics’ oral drug candidate for sickle cell disease (SCD), boosted fetal hemoglobin (HbF) levels and reduced red blood cell destruction — thereby easing symptoms of anemia — in a small group of patients with the blood disorder. These are the latest results…
Most women and girls with sickle cell disease (SCD) experience disease-related pain during menstrual periods, but many are unaware that medical treatments — such as birth control pills — may help alleviate period-related pain in SCD, according to a new study by U.S. researchers. Based on these findings, the…
As they shift from pediatric to adult care, young adults with sickle cell disease (SCD) appear to visit the emergency room more often and be prescribed less hydroxyurea, a preventive treatment approved to reduce the frequency of painful crises, according to a study in the U.S. Data also…
A small clinical trial testing Agios Pharmaceuticals’ oral therapy candidate tebapivat against a placebo for easing symptoms in people with sickle cell disease (SCD) has completed enrollment, the company announced. Agios expects to report early results from the Phase 2 trial later this year, according to a…
Differences in the stiffness of red blood cells may help to explain variations in the severity of sickle cell disease (SCD), according to a new study. The findings shed new light on the physics that govern the flow of deformed blood cells through vessels. Researchers found that stiff cells…
The Food and Drug Administration (FDA) has granted breakthrough device designation to the Gazelle Hb Variant test, a point-of-care blood test developed by Hemex Health to enable rapid, low-cost diagnosis of sickle cell disease (SCD) and beta thalassemia. The designation is…
Recent Posts
- Transplant outperforms standard care for children with sickle cell
- Key lessons I’ve learned as a doctor about my childhood corticosteroid use
- Boozer brothers join NMDP to boost stem cell donor registry
- Why the global sickle cell disease community needs more research
- Mitapivat raises hemoglobin levels in Phase 3 sickle cell disease trial
- FDA reviewing Casgevy for children with sickle cell as young as 5
- When a sickle cell pain crisis interrupts a stretch of good health, part 2
- Gene-editing therapy frees first trial participant from SCD symptoms
- Why I refused to stay silent about my sickle cell disease
- Stem cell transplant for SCD beats gene therapy on cost: Study